Peptide Having Affinity for Human Transferrin Receptor
AssigneeJCR Pharmaceuticals Co., Ltd.
InventorsTakashi Onouchi, Kenichi Takahashi
Life of this patent
Estimating the term…
Abstract
The present invention relates, in one embodiment thereof, to a peptide having affinity for human transferrin receptor, which can be used for binding to any of compounds (a protein, a nucleic acid, a low molecular weight compound, and the like) that should be caused to function in the central nervous system (CNS), in order to allow the compound to pass through the blood-brain barrier, and the use of the peptide. The peptide is, for example, a peptide having the amino acid sequence selected from the group consisting of amino acid sequences set forth in SEQ ID NOs:3 to 7 and 55, or a mutant thereof.
Claims22
(canceled)
2:
- A human transferrin receptor affinity peptide selected from the group consisting of the following (1) to (6):
- (1) a peptide having the amino acid of SEQ ID NO:3;
- (2) a peptide having the amino acid sequence of SEQ ID NO:4;
- (3) a peptide having the amino acid sequence of SEQ ID NO:5;
- (4) a peptide having the amino acid sequence of SEQ ID NO:6;
- (5) a peptide having the amino acid sequence of SEQ ID NO:7;
- and
- (6) a peptide having the amino acid sequence of SEQ ID NO:55, wherein the peptide has the ability to pass through the blood brain barrier.
-8. (canceled)
9:
- The human transferrin receptor affinity peptide according to claim 2, wherein the human transferrin receptor affinity peptide has affinity for both an extracellular region of human transferrin receptor and an extracellular region of monkey transferrin receptor.
(canceled)
11:
- The human transferrin receptor affinity peptide according to claim 9, wherein a dissociation constant with the extracellular region of human transferrin receptor is 8×10−9 to 2×10−8.
(canceled)
13:
- The human transferrin receptor affinity peptide according to claim 9, wherein when the value of the dissociation constant with the extracellular region of human transferrin receptor is taken as 1, the value of the dissociation constant with the monkey transferrin receptor is 0.7 to 1.2.
-17. (canceled)
18:
- A human transferrin receptor affinity peptide-drug complex, wherein the human transferrin receptor affinity peptide according to claim 2 is linked to a drug.
19:
- The complex according to claim 18, wherein the drug is any one of a different protein (A), a nucleic acid, or a low molecular weight compound.
20:
- A fusion protein comprising:
- the human transferrin receptor affinity peptide according to claim 2 and
- a different protein (A).
21:
- The fusion protein according to claim 20, wherein the human transferrin receptor affinity peptide is bound to the C-terminus of the different protein (A) directly or via a linker.
22:
- The fusion protein according to claim 20, wherein the human transferrin receptor affinity peptide is bound to the N-terminus of the different protein (A) directly or via a linker.
-26. (canceled)
27:
- The fusion protein according to claim 20, wherein the different protein (A) is a cytokine, a growth factor, or an antibody medicine.
28:
- The fusion protein according to claim 20, wherein the different protein (A) is selected from the group consisting of a brain-derived neurotrophic factor (BDNF), a nerve growth factor (NGF), a lysosomal enzyme, a ciliary neurotrophic factor (CNTF), a glial cell-derived neurotrophic factor (GDNF), a neurotrophin 3, a neurotrophin 4/5, a neurotrophin 6, a neuregulin 1, an erythropoietin, a darbepoietin, an activin, a basic fibroblast growth factor (bFGF), a fibroblast growth factor 2 (FGF2), an epidermal growth factor (EGF), a vascular endothelial growth factor (VEGF), an interferon α, an interferon β, an interferon γ, an interleukin 6, a granulocyte-macrophage colony-stimulating factor (GM-CSF), a granulocyte-colony-stimulating factor (G-CSF), a macrophage colony-stimulating factor (M-CSF), a tumor necrosis factor-α receptor (TNF-α receptor), a PD-1 ligand, a PD-L1, a PD-L2, an enzyme having an activity of degrading beta-amyloid, an anti-beta-amyloid antibody, an anti-BACE antibody, an anti-EGFR antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-HER2 antibody, an anti-TNF-α antibody, and an anti-CTLA-4 antibody.
29:
- The fusion protein according to claim 20, wherein the different protein (A) is a lysosomal enzyme, and the lysosomal enzyme is selected from the group consisting of α-L-iduronidase, iduronate-2-sulfatase, acidic α-glucosidase, glucocerebrosidase, β-galactosidase, GM2 activator protein, β-hexosaminidase A, β-hexosaminidase B, N-acetylglucosamine-1-phosphotransferase, α-mannosidase, β-mannosidase, galactosylceramidase, saposin C, allylsulfatase A, α-L-fucosidase, aspartylglucosaminidase, α-N-acetylgalactosaminidase, acidic sphingomyelinase, α-galactosidase A, β-glucuronidase, heparan-N-sulfatase, α-N-acetylglucosaminidase, acetyl CoA α-glucosaminide N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, acidic ceramidase, amylo-1,6-glucosidase, sialidase, palmitoyl protein thioesterase-1, tripeptidyl peptidase-1, hyaluronidase-1, CLN1, and CLN2.
-31. (canceled)
32:
- A nucleic acid encoding the human transferrin receptor affinity peptide according to claim 2.
33:
- A nucleic acid encoding the fusion protein according to claim 20.
-36. (canceled)
Dependencies are inferred from the claim text.